NEOS Investment Management LLC Purchases 37,533 Shares of Genmab A/S (NASDAQ:GMAB)

NEOS Investment Management LLC grew its position in shares of Genmab A/S (NASDAQ:GMAB) by 91.2% in the 4th quarter, HoldingsChannel reports. The firm owned 78,683 shares of the company’s stock after acquiring an additional 37,533 shares during the quarter. NEOS Investment Management LLC’s holdings in Genmab A/S were worth $1,642,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. JPMorgan Chase & Co. raised its stake in shares of Genmab A/S by 3,049.3% during the fourth quarter. JPMorgan Chase & Co. now owns 407,613 shares of the company’s stock worth $8,507,000 after acquiring an additional 394,670 shares in the last quarter. LPL Financial LLC raised its position in Genmab A/S by 3.3% in the 4th quarter. LPL Financial LLC now owns 195,436 shares of the company’s stock worth $4,079,000 after purchasing an additional 6,288 shares during the period. Sei Investments Co. lifted its stake in Genmab A/S by 55.2% in the fourth quarter. Sei Investments Co. now owns 57,702 shares of the company’s stock worth $1,205,000 after purchasing an additional 20,525 shares during the last quarter. Signaturefd LLC boosted its position in Genmab A/S by 163.2% during the fourth quarter. Signaturefd LLC now owns 20,790 shares of the company’s stock valued at $434,000 after buying an additional 12,890 shares during the period. Finally, Madison Investment Advisors LLC bought a new position in shares of Genmab A/S during the fourth quarter valued at about $979,000. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Genmab A/S Trading Down 1.2 %

Shares of NASDAQ GMAB opened at $19.90 on Friday. The firm has a fifty day simple moving average of $20.89 and a two-hundred day simple moving average of $21.88. Genmab A/S has a 12 month low of $18.64 and a 12 month high of $30.50. The firm has a market capitalization of $13.17 billion, a PE ratio of 11.44, a price-to-earnings-growth ratio of 2.65 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. On average, sell-side analysts predict that Genmab A/S will post 1.45 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on GMAB shares. William Blair upgraded Genmab A/S from a “market perform” rating to an “outperform” rating in a report on Tuesday, March 11th. HC Wainwright reissued a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a research note on Thursday, January 23rd. Leerink Partners upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 target price on the stock in a report on Thursday, February 13th. BNP Paribas upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 11th. Finally, Leerink Partnrs raised shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Thursday, February 13th. Four equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $41.33.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.